Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMY2KX9)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
| |||||
| Therapeutic Class | Bone Density Conservation Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Fibroblast
Nasopharyngeal carcinoma
Liver
Hepatocellular carcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||